Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Debashree BasakDivision of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Puspendu GhoshDivision of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India.ORCID 0000-0003-0920-2306
Anupam GautamInstitute for Bioinformatics and Medical Informatics, University of Tübingen, Tübingen, Germany.ORCID 0000-0002-6460-6525
Ishita SarkarDivision of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Arpita BhoumikDivision of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India.ORCID 0000-0002-0842-4487
Soham ChowdhuryDivision of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India.ORCID 0009-0001-3933-6551
Shaun MahantiDivision of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India.ORCID 0009-0000-9427-6945
Anwesha MandalDivision of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India.ORCID 0009-0003-0113-211X
Rajeswari ChakrabortyDivision of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Anwesha KarDivision of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India.ORCID 0000-0002-4455-6276
Snehanshu ChowdhuryDivision of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India.ORCID 0000-0002-7114-4656
Krishna KumarDivision of Structural Biology and Bioinformatics, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India.ORCID 0000-0001-5986-7248
Shubhrajit BarmanAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.ORCID 0009-0006-0981-4424
Senthil Kumar GanesanDivision of Structural Biology and Bioinformatics, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India.ORCID 0000-0001-6040-4814
Saikat ChakrabartiDivision of Structural Biology and Bioinformatics, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Sandip PaulCenter for Health Science and Technology, JIS Institute of Advanced Studies and Research, JIS University, Kolkata, India.ORCID 0000-0001-7406-3598
Shilpak ChatterjeeDivision of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence; CSIR-Indian Institute of Chemical Biology, Kolkata, India. schatterjee@iicb.res.in.ORCID 0000-0002-8428-6434
Funding
CSIR - Indian Institute of Chemical Biology (CSIR-IICB) MLP-121CSIR - Indian Institute of Chemical Biology (CSIR-IICB) P50Deutsche Forschungsgemeinschaft (DFG) INST 37/935-1 FUGGDST | Science and Engineering Research Board (SERB) CRG/2019/001334German Network for Bioinformatics Infrastructure (de.NBI) W-de.NBI-001,W-de.NBI-004,W-de.NBI-008,W-de.NBI-010,W-de.NBI-013,W-de.NBI-014,W-de.NBI-016,W-de.NBI-022
6 · The paper itself
Abstract
Sphingosine-1-phosphate receptor 1 (S1PR1) signaling has been linked to the regulation of immunosuppressive cell populations within the tumor microenvironment (TME); however, its role in shaping anti-tumor CD8⁺ T cell responses remains poorly defined. Herein, we demonstrate that intratumoral CD8⁺ T cells express S1PR1, with expression predominantly enriched in the terminally exhausted subset. Transcriptomic profiling, combined with pharmacological inhibition and genetic knockdown, reveals that S1PR1-S1P signaling activates the PERK (protein kinase R (PKR)-like endoplasmic reticulum kinase)-CHOP (C/EBP homologous protein) axis of the endoplasmic reticulum stress response. CHOP, in turn, upregulates transcription of Map3k13 and Map3k15, triggering downstream MAPK signaling and culminating in activation of p38MAPK. Activation of this pathway impairs CD8⁺ T cell metabolism and effector function while increasing apoptotic susceptibility. This ultimately limits the persistence and accumulation of functional CD8⁺ T cells within the TME, thereby compromising their responsiveness to anti-PD-1 therapy. Targeting the S1PR1-S1P axis or its downstream effectors offers a promising strategy to improve cancer immunotherapy outcomes.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
S1P-S1PR1 signaling impairs CD8 · full record | OpenQuestion